Fueling innovation across life sciences
From cutting-edge startups to established enterprises, companies rely on licensing and strategic partnerships to turn innovative science into successful business models. Our lawyers are here to assist with customized strategies, leveraging their scientific and technical knowledge to help you plan, negotiate, and finalize agreements and financing that fuel your growth.
From securing business-critical financing to entering transformative R&D partnerships, licensing and strategic transactions are essential for driving growth and success in life sciences. We’re here to creatively draft, negotiate, execute, and manage your most strategic engagements to maximize opportunity at all stages of your product lifecycle.
Life sciences licensing and strategic transactions require multidimensional counsel to help navigate a broad range of legal topics ranging from IP and regulatory to tax and antitrust. Our deep bench of life sciences-savvy lawyers across renowned practices delivers the right mix of knowledge, no matter the challenge. From the moment you consider engaging in a collaborative relationship or financing arrangement, we work to deliver strategic, value-added counsel at every stage.
“DLA Piper is an excellent firm with a great approach to problem-solving. The team has a great deal of breadth and depth and is extremely responsive.”
Our life sciences lawyers are smart on science, and many are scientists by training who hold MDs, PhDs or other advanced degrees in the field. We speak the language and craft legal strategies informed by both legal knowledge and technological nuance. And because members of our team have decades of in-house life sciences experience, our solutions are informed by real world experience.
Awards and recognition
Experience
- An American pharmaceutical company in connection with an analysis on AI-enabled research tool, collaboration agreements, and licenses, and development of playbook for negotiation of AI-enabled tech transactions for life science research tools for future use.
- An international specialty pharma group in its acquisition of a medication to treat Alzheimer’s disease.
- A leading global medical technology and digital solutions innovator on an investment in and a commercial collaboration agreement with a leading cardiac imaging software company.
- Intercept Pharmaceuticals (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, in the USD450 million sale of certain foreign subsidiaries and rights regarding Intercept’s international operations to Advanz Pharma, a private equity-backed pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe.
- Launch Therapeutics in formation of an SPV established to provide up to USD106 million in non-dilutive financing for clinical trials by Pathalys Pharma, Inc.
- Liquidia Technologies, Inc. (Nasdaq: LDQA), a US-based biopharmaceutical company, in connection with its entry into a Revenue Interest Financing Agreement with HealthCare Royalty (HCRx) for a total investment amount of up to USD100 million.
- Taysha Gene Therapies in connection with licensing and inventory purchase agreements for ABO-202, a clinical stage, novel, one-time gene therapy for CLN1 Disease.
- TG Therapeutics, Inc. in connection with a USD650 million ex-US commercialization agreement with Neuraxpharm Group for BRIUMVI® (ublituximab), an anti-CD20 monoclonal antibody approved in the United States (US) and European Union (EU) for adult patients with relapsing forms of multiple sclerosis (RMS).
- The Trustees of the University of Pennsylvania in connection with exclusive licensing and collaboration agreements with various venture-backed emerging growth biotech companies for gene therapy products and gene editing technologies in exchange for upfront and milestone payments, royalties and sponsored research funding.
- Vertex Pharmaceuticals in the negotiation of an agreement with Lonza for a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with type 1 diabetes.
Featured insights
A series in which DLA Piper’s Life Sciences team helps to deepen your understanding of sector-specific commercial agreements and their clauses.
In DLA Piper's At the Intersection of Science and Law podcast series, members of the firm's Life Sciences team will explore the connection between science and the law in areas including AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.
